Search

Author/Creator Matous, Jeffrey

2. Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial. Issue 6 (12th May 2022)

Authors:
Bahlis, Nizar J.; Siegel, David S.; Schiller, Gary J.; Samaras, Christy; Sebag, Michael; Berdeja, Jesus; Ganguly, Siddhartha; Matous, Jeffrey; Song, Kevin; Seet, Christopher S.; Acosta-Rivera, Mirelis; Bar, Michael; Quick, Donald; Anz, Bertrand; Fonseca, Gustavo; Chung, Weiyuan; Lee, Kim; Mouro, ...
Journal:
Leukemia & lymphoma
Issue:
Volume 63:Issue 6(2022)
Page Start:
1407
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Three‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma. (12th February 2020)

Authors:
LaCasce, Ann S.; Bociek, R. Gregory; Sawas, Ahmed; Caimi, Paolo; Agura, Edward; Matous, Jeffrey; Ansell, Stephen M.; Crosswell, Howland E.; Islas‐Ohlmayer, Miguel; Behler, Caroline; Cheung, Eric; Forero‐Torres, Andres; Vose, Julie; O'Connor, Owen A.; Josephson, Neil; Wang, Yinghui; Advani, Ranjana
Journal:
British journal of haematology
Issue:
Volume 189:Number 3(2020)
Page Start:
e86
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗